M

Mural Oncology PLC
NASDAQ:MURA

Watchlist Manager
Mural Oncology PLC
NASDAQ:MURA
Watchlist
Price: 2.04 USD Market Closed
Market Cap: 35.4m USD

Mural Oncology PLC
Tax Provision

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Mural Oncology PLC
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
M
Mural Oncology PLC
NASDAQ:MURA
Tax Provision
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Alkermes Plc
NASDAQ:ALKS
Tax Provision
-$62.8m
CAGR 3-Years
N/A
CAGR 5-Years
-31%
CAGR 10-Years
-14%
Amarin Corporation PLC
NASDAQ:AMRN
Tax Provision
-$1.1m
CAGR 3-Years
54%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Prothena Corporation PLC
NASDAQ:PRTA
Tax Provision
-$41.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-48%
No Stocks Found

Mural Oncology PLC
Glance View

Market Cap
35.3m USD
Industry
Biotechnology

Mural Oncology PLC is a IE-based company operating in Biotechnology industry. Mural Oncology plc is a clinical-stage oncology company. The firm is leveraging its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. The company leverages its expertise in cytokine biology, immune cell modulation and protein engineering capabilities to develop immunotherapies. The firm is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. Its portfolio of programs includes Nemvaleukin alfa (Nemvaleukin)-IL-2, IL-12, and IL-18. Nemvaleukin is an engineered interleukin-2 (IL-2) variant designed to harness the potent anti-cancer capabilities of high-dose rhIL-2 while minimizing toxicity by selectively activating cancer-fighting CD8 T cells and NK cells. The tumor-targeted split IL-12 program focuses on delivering the therapeutic potential of IL-12 by splitting it into inactive component.

MURA Intrinsic Value
8.33 USD
Undervaluation 76%
Intrinsic Value
Price
M

See Also

What is Mural Oncology PLC's Tax Provision?
Tax Provision
0 USD

Based on the financial report for Dec 31, 2024, Mural Oncology PLC's Tax Provision amounts to 0 USD.

Back to Top